RPRX — Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology
$62.12
-$0.20 (-0.32%)
Royalty Pharma Plc (RPRX) is a biotechnology company listed on NASDAQ. It is led by Pablo Gerardo Legorreta, based in 110 East 59th Street, New York, NY, United States, 10022. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Latest reported RPRX revenue for 2025-09-30 was $609.3M. Net income was $444.2M. Revenue was up 5.3% from 2025-06-30 to 2025-09-30. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.
Use this RPRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RPRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RPRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Royalty Pharma Plc even when a live quote feed is slow.
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
RPRX Key Statistics
Market Cap
$20.45B
Volume
490,507
Previous Close
$62.07
Day Range
$61.49 – $62.28
P/E Ratio
14.84
EPS
$1.91
Revenue
$2.26B
Net Income
$1.33B
Gross Profit
$0.00
Free Cash Flow
$0.00
Dividend Yield
2.44%
Revenue Growth
-3.9%
Profit Margin
58.8%
RPRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $2.26B | $2.35B | $2.24B | $2.29B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $1.33B | $1.70B | $230.06M | $1.24B |
| EPS (Diluted) | $1.91 | $2.53 | $0.10 | $1.49 |
Total Assets
$18.22B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$929.03M
Operating Cash Flow
$2.77B
Free Cash Flow
$0.00
Royalty Pharma Plc Company Information
- Founder, Chairman of the Board & CEO
- Pablo Gerardo Legorreta
- Headquarters
- 110 East 59th Street, New York, NY, United States, 10022
- Website
- www.royaltypharma.com
- Phone
- 212 883 0200
- IPO / Founded
- 1993-03-25
- Sector
- Healthcare
- Industry
- Biotechnology